AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38324512 — intervention group
Group type: EXPERIMENTAL
Intervention: Providence-type brace optimized by the semi-automatic algorithm (Test)
Number of subjects: 58
Study 38324584 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-directed intervention (free ACT for positive RDT)
Number of subjects: 39
Study 38324584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined client and provider-directed intervention (free ACT for positive RDT and $0.1 for each RDT performed)
Number of subjects: 39
Study 38324584 — intervention group
Group type: COMPARATOR
Intervention: Control arm (subsidized mRDT testing at $0.4)
Number of subjects: 39
Study 38324584 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-directed intervention and combined intervention
Number of subjects: 39
Study 38324741 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenolanib plus intensive chemotherapy
Number of subjects: 44
Study 38324741 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy alone (control group)
Number of subjects: 44
Study 38324744 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 38324744 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 38324766 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1647
Number of subjects: 0
Study 38324766 — intervention group
Group type: COMPARATOR
Intervention: gB/MF59
Number of subjects: 0
Study 38325276 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733
Study 38325276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 38325290 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin Skin Testing (PST) followed by amoxicillin 250 mg challenge
Number of subjects: 206
Study 38325290 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Oral Challenge (GOC) with amoxicillin 25 mg followed by 250 mg
Number of subjects: 206
Study 38325290 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study completion
Number of subjects: 206
Study 38325290 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider surveys
Number of subjects: 206
Study 38325290 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-assessment questionnaire
Number of subjects: 206
Study 38325328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks in conjunction with glass yttrium-90 (Y90) radioembolization TheraSphere
Number of subjects: 27
Study 38325411 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir (GLE/PIB)
Number of subjects: 115
Study 38325518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173
Study 38325518 — intervention group
Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173
Study 38325518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DBT and IGST
Number of subjects: 173
Study 38325649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone microarchitecture in people with SCI
Number of subjects: 20
Study 38325649 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading
Number of subjects: 20
Study 38325649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture prevention strategies
Number of subjects: 20
Study 38325673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulated Ambulation Score (CAS) assessed by two independent physiotherapists
Number of subjects: 60
Study 38325765 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 1.08 g⋅kg
Number of subjects: 16
Study 38325765 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 38325896 — intervention group
Group type: EXPERIMENTAL
Intervention: Local coalitions with training and technical assistance for smoke-free policy development and enforcement
Number of subjects: 28
Study 38325896 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 28
Study 38325988 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) combined with medical therapy (MT)
Number of subjects: 100
Study 38325988 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MT) alone
Number of subjects: 100
Study 38326228 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 566
Study 38326228 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 566
Study 38326260 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental Step Test (IST)
Number of subjects: 63
Study 38326267 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention package including peer support, mobile phone messaging, and birthing kits during pregnancy
Number of subjects: 1877
Study 38326267 — intervention group
Group type: COMPARATOR
Intervention: Routine government health services (standard of care)
Number of subjects: 1877
Study 38326267 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention package
Number of subjects: 1877
Study 38326267 — intervention group
Group type: COMPARATOR
Intervention: Integrated intervention package and Routine government health services
Number of subjects: 1877
Study 38326271 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CPR-AED training
Number of subjects: 0
Study 38326352 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg daily)
Number of subjects: 64
Study 38326352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 38326432 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 11
Study 38326432 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg)
Number of subjects: 11
Study 38326493 — intervention group
Group type: EXPERIMENTAL
Intervention: School social intervention
Number of subjects: 90
Study 38326493 — intervention group
Group type: COMPARATOR
Intervention: Typical school programming (services-as-usual [SAU])
Number of subjects: 90
Study 38326577 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166 radioembolization
Number of subjects: 37
Study 38326734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HIRT) for 16 months, twice weekly
Number of subjects: 31
Study 38326734 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 31
Study 38326736 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 136
Study 38326736 — intervention group
Group type: COMPARATOR
Intervention: Sinus rhythm (SR) group
Number of subjects: 136
Study 38326736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AF and SR groups
Number of subjects: 136
Study 38326814 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mpodera vCoP
Number of subjects: 185
Study 38326832 — intervention group
Group type: EXPERIMENTAL
Intervention: iHEAL intervention delivered by Registered Nurses over 6-7 months
Number of subjects: 331
Study 38326832 — intervention group
Group type: EXPERIMENTAL
Intervention: iHEAL intervention
Number of subjects: 331
Study 38326832 — intervention group
Group type: COMPARATOR
Intervention: Control (community service information)
Number of subjects: 331
Study 38326847 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Detectives In-Out program (blended version of the Unified Protocol for Children)
Number of subjects: 138
Study 38326847 — intervention group
Group type: COMPARATOR
Intervention: Coping Cat program (evidenced-based group intervention for children with anxiety disorders)
Number of subjects: 138
Study 38326858 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate 20 mg/kg administered daily in capsules for two weeks on followed by ten weeks off for 12 months
Number of subjects: 0
Study 38326858 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily in capsules for two weeks on followed by ten weeks off for 12 months
Number of subjects: 0
Study 38326858 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0
Study 38326858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38326920 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum albumin 20% 100 mL over 15 min
Number of subjects: 50
Study 38326920 — intervention group
Group type: COMPARATOR
Intervention: Saline 500 mL
Number of subjects: 50
Study 38327509 — intervention group
Group type: COMPARATOR
Intervention: Pre-pandemic levels
Number of subjects: 1843
Study 38327509 — intervention group
Group type: EXPERIMENTAL
Intervention: During the pandemic
Number of subjects: 1843
Study 38327730 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-free treatment
Number of subjects: 183
Study 38327730 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 183
Study 38327981 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38328552 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-part mechanotherapy (Flyte) for 12 weeks
Number of subjects: 144
Study 38328552 — intervention group
Group type: COMPARATOR
Intervention: Part 1 therapy for 6 weeks followed by full therapy
Number of subjects: 144
Study 38328709 — intervention group
Group type: EXPERIMENTAL
Intervention: inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m2 weekly)
Number of subjects: 30
Study 38328709 — intervention group
Group type: EXPERIMENTAL
Intervention: inetetamab, pyrotinib, and oral vinorelbine
Number of subjects: 30
Study 38328752 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac joint fusion
Number of subjects: 63
Study 38328752 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 63
Study 38328915 — intervention group
Group type: EXPERIMENTAL
Intervention: New hypertension diagnosis
Number of subjects: 323
Study 38328915 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved target BP control
Number of subjects: 323
Study 38328915 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP change
Number of subjects: 323
Study 38328915 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP change
Number of subjects: 323
Study 38328915 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving BP control
Number of subjects: 323
Study 38328915 — intervention group
Group type: COMPARATOR
Intervention: Undiagnosed hypertension
Number of subjects: 323
Study 38328938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccinated children
Number of subjects: 0
Study 38328938 — intervention group
Group type: COMPARATOR
Intervention: Nonvaccinated children
Number of subjects: 0
Study 38329108 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P
Number of subjects: 261
Study 38329108 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 261
Study 38329117 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mediators in EDs
Number of subjects: 50429
Study 38329117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mediators)
Number of subjects: 50429
Study 38329130 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-treated individuals (N = 12)
Number of subjects: 45
Study 38329130 — intervention group
Group type: COMPARATOR
Intervention: Chronic-treated participants (N = 33)
Number of subjects: 45
Study 38329130 — intervention group
Group type: COMPARATOR
Intervention: Chronic-treated individuals (N = 33)
Number of subjects: 45
Study 38329130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 38329148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg, up to 25 mg)
Number of subjects: 458
Study 38329148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 38329153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 7 weeks
Number of subjects: 88
Study 38329153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study 38329180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pandemic group (n=1166)
Number of subjects: 2938
Study 38329180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic group (n=979)
Number of subjects: 2938
Study 38329180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic group
Number of subjects: 2938
Study 38329180 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 2938
Study 38329222 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 311
Study 38329404 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing chemotherapy
Number of subjects: 98
Study 38329404 — intervention group
Group type: COMPARATOR
Intervention: Short-time cardiac MRI in healthy female controls
Number of subjects: 98
Study 38329404 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing immediate chemotherapy
Number of subjects: 98
Study 38329404 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-time cardiac MRI in breast cancer participants undergoing remote chemotherapy
Number of subjects: 98
Study 38329405 — intervention group
Group type: EXPERIMENTAL
Intervention: Periaortic adipose tissue attenuation in patients with abdominal aortic aneurysms (both asymptomatic and symptomatic)
Number of subjects: 0
Study 38329405 — intervention group
Group type: COMPARATOR
Intervention: Controls without aneurysms
Number of subjects: 0
Study 38329507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant (super-)selective infusion of holmium-166 microspheres after radiofrequency ablation
Number of subjects: 12
Study 38329642 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT + real iTBS
Number of subjects: 17
Study 38329642 — intervention group
Group type: COMPARATOR
Intervention: mCIMT + sham iTBS
Number of subjects: 17
Study 38329642 — intervention group
Group type: COMPARATOR
Intervention: mCIMT alone
Number of subjects: 17
Study 38329646 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ocedurenone administered orally
Number of subjects: 2
Study 38329716 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg once daily
Number of subjects: 469
Study 38329728 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study 38329732 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment in breast cancer cohorts
Number of subjects: 0
Study 38329732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing phase II clinical trial for glioblastoma patients
Number of subjects: 0
Study 38329737 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy in combination with radiotherapy (IC-RT) group
Number of subjects: 383
Study 38329737 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy combined with chemoradiotherapy (IC-CCRT) group
Number of subjects: 383
Study 38329737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 383
Study 38329745 — intervention group
Group type: EXPERIMENTAL
Intervention: MW032
Number of subjects: 708
Study 38329745 — intervention group
Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 708
Study 38329746 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT (30 to 40 sessions over 6 to 8 weeks)
Number of subjects: 189
Study 38329746 — intervention group
Group type: COMPARATOR
Intervention: Control (no HBOT)
Number of subjects: 189
Study 38329757 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised multicomponent exercise program during hospitalization and health education on how to exercise at home with telephone counseling during follow-up.
Number of subjects: 260
Study 38329757 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 260
Study 38329779 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) consisting of information on the risk of inappropriate use and individualized advice on how to reduce use.
Number of subjects: 5
Study 38329779 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 5
Study 38329790 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese electroacupuncture (30 minutes per session, 2 sessions per week for 8 weeks)
Number of subjects: 168
Study 38329790 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese electroacupuncture
Number of subjects: 168
Study 38329790 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 pair of electrically charged needles on the head)
Number of subjects: 168
Study 38329790 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study 38329996 — intervention group
Group type: EXPERIMENTAL
Intervention: My Choice-My Way! leaving care program
Number of subjects: 0
Study 38329996 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 0
Study 38330026 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic adhesive tape
Number of subjects: 768
Study 38330026 — intervention group
Group type: COMPARATOR
Intervention: Fixation cord with PVC sheath
Number of subjects: 768
Study 38330045 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of antiretroviral therapy (ART)
Number of subjects: 0
Study 38330045 — intervention group
Group type: COMPARATOR
Intervention: TB results first approach (ART only after active TB has been confirmed or refuted)
Number of subjects: 0
Study 38330045 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of ART
Number of subjects: 0
Study 38330169 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38330179 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (M/M arm)
Number of subjects: 40
Study 38330179 — intervention group
Group type: COMPARATOR
Intervention: Mitapivat (P/M arm after week 24)
Number of subjects: 40
Study 38330179 — intervention group
Group type: COMPARATOR
Intervention: Mitapivat (P/M arm)
Number of subjects: 40
Study 38330285 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg alone or in combination with nusinersen (Cohort 1)
Number of subjects: 58
Study 38330285 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg combined with nusinersen (Cohort 2)
Number of subjects: 58
Study 38330285 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitegromab 2 mg/kg combined with nusinersen (Cohort 3)
Number of subjects: 58
Study 38330285 — intervention group
Group type: EXPERIMENTAL
Intervention: Apitegromab 20 mg/kg combined with nusinersen (Cohort 3)
Number of subjects: 58
Study 38330306 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting (RP) intervention
Number of subjects: 212
Study 38330306 — intervention group
Group type: COMPARATOR
Intervention: Safety control condition
Number of subjects: 212
Study 38330355 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal severe mental illness (SMI)
Number of subjects: 93
Study 38330355 — intervention group
Group type: COMPARATOR
Intervention: No maternal diagnosis
Number of subjects: 93
Study 38330357 — intervention group
Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 10 µg × 3
Number of subjects: 49
Study 38330357 — intervention group
Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 30 µg × 3
Number of subjects: 49
Study 38330357 — intervention group
Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 60 µg × 3
Number of subjects: 49
Study 38330357 — intervention group
Group type: EXPERIMENTAL
Intervention: rCSP/GLA-LSQ 60 µg × 2
Number of subjects: 49
Study 38330357 — intervention group
Group type: EXPERIMENTAL
Intervention: rCSP 30 µg alone × 3
Number of subjects: 49
Study 38330357 — intervention group
Group type: COMPARATOR
Intervention: Infectivity controls
Number of subjects: 49
Study 38330368 — intervention group
Group type: EXPERIMENTAL
Intervention: BSHAPE intervention
Number of subjects: 144
Study 38330368 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 144
Study 38330377 — intervention group
Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet (25 mg dose)
Number of subjects: 86
Study 38330377 — intervention group
Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet (10 mg or 50 mg doses)
Number of subjects: 86
Study 38330377 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 86
Study 38330377 — intervention group
Group type: EXPERIMENTAL
Intervention: RKP00156 vaginal tablet
Number of subjects: 86
Study 38330380 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical debulking of bulky or multiple lymph nodes before concurrent chemoradiation therapy (CCRT)
Number of subjects: 0
Study 38330380 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation therapy (CCRT)
Number of subjects: 0
Study 38330409 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily glucose monitoring
Number of subjects: 197
Study 38330409 — intervention group
Group type: COMPARATOR
Intervention: Every-other-day glucose monitoring
Number of subjects: 197
Study 38330866 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy intervention
Number of subjects: 14
Study 38330866 — intervention group
Group type: COMPARATOR
Intervention: No preoperative physiotherapy intervention
Number of subjects: 14
Study 38330942 — intervention group
Group type: EXPERIMENTAL
Intervention: ADG106 (5.0 mg/kg dose level)
Number of subjects: 62
Study 38330942 — intervention group
Group type: EXPERIMENTAL
Intervention: ADG106 (10.0 mg/kg dose level)
Number of subjects: 62
Study 38330942 — intervention group
Group type: EXPERIMENTAL
Intervention: ADG106
Number of subjects: 62
Study 38330975 — intervention group
Group type: EXPERIMENTAL
Intervention: Onradivir 200 mg twice per day
Number of subjects: 172
Study 38330975 — intervention group
Group type: EXPERIMENTAL
Intervention: Onradivir 400 mg twice per day
Number of subjects: 172
Study 38330975 — intervention group
Group type: EXPERIMENTAL
Intervention: Onradivir 600 mg once per day
Number of subjects: 172
Study 38330975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 38330975 — intervention group
Group type: EXPERIMENTAL
Intervention: All onradivir groups
Number of subjects: 172
Study 38330980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 2387
Study 38330980 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-vitro fertilisation (IVF)
Number of subjects: 2387
Study 38330987 — intervention group
Group type: EXPERIMENTAL
Intervention: Survodutide 0.6 mg
Number of subjects: 387